Patents
OxyBridge™ is protected by granted patents in the United States, Europe and Australia, with further applications pending. Each granted patent is listed below by publication number, jurisdiction and date, and can be looked up in the issuing office’s own register.
Granted
| Patent | Jurisdiction | Title | Granted |
|---|---|---|---|
| US 11,504,417 B2United States · 2022 | United States | Blood substitutes comprising hemoglobin and methods of making | 2022 |
| US 12,582,703 B2United States · 2026 | United States | Blood substitutes comprising hemoglobin and methods of making | 2026 |
| AU 2018304174Australia · 23 October 2025 | Australia | Blood substitutes comprising hemoglobin and methods of making | 23 October 2025 |
| EP 4167961Europe · 29 April 2026Registered as a Unitary Patent across 18 member states. | Europe | Compositions and methods for treating hemorrhagic shock | 29 April 2026 |
Pending
18 international patent applications are pending.